Janne Brouckaert

Janne Brouckaert

Auto-generated profile, based on publicly available information

Janne Brouckaert

University Hospitals Leuven, Leuven, Belgium

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2023 in eClinicalMedicine
Verified
Journal Article
Open access
JLJohn Louca
John Louca
MÖMarco Öchsner
Marco Öchsner
ASAshish Shah
Ashish Shah
JHJordan Hoffman
Jordan Hoffman
ADAlexandra Debose-Scarlett
Alexandra Debose-Scarlett
LCLaurens Ceulemans
Laurens Ceulemans
Heart transplantation is an effective treatment offering the best recovery in both quality and quantity of life in those affected by refractory, severe heart failure. However, transplantation is limited by donor organ availability. The reintroduction of heart donation after the circulatory determination of death (DCD) in 2014 offered an uplift in transplant activity by 30%. Thoraco-abdominal normothermic regional perfusion (taNRP) enables in-situ reperfusion of the DCD heart. The objective of this paper is to assess the clinical outcomes of DCD donor hearts recovered and transplanted from donors undergoing taNRP. This was a multicentre retrospective observational study. Outcomes included functional warm ischaemic time, use of mechanical support immediately following transplantation, perioperative and long-term actuarial survival and incidence of acute rejection requiring treatment. 157 taNRP DCD heart transplants, performed between February 2, 2015, and July 29, 2022, have been included from 15 major transplant centres worldwide including the UK, Spain, the USA and Belgium. 673 donations after the neurological determination of death (DBD) heart transplantations from the same centres were used as a comparison group for survival. taNRP resulted in a 23% increase in heart transplantation activity. Survival was similar in the taNRP group when compared to DBD. 30-day survival was 96.8% ([92.5%-98.6%] 95% CI, n = 156), 1-year survival was 93.2% ([87.7%-96.3%] 95% CI, n = 72) and 5-year survival was 84.3% ([69.6%-92.2%] 95% CI, n = 13). Our study suggests that taNRP provides a significant boost to heart transplantation activity. The survival rates of taNRP are comparable to those obtained for DBD transplantation in this study. The similar survival may in part be related to a short warm ischaemic time or through a possible selection bias of younger donors, this being an uncontrolled observational study. Therefore, our study suggests that taNRP offers an effective method of organ preservation and procurement. This early success of the technique warrants further investigation and use. None of the authors have a financial relationship with a commercial entity that has an interest in the subject.

26 July 2024 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
JBJanne Brouckaert
Janne Brouckaert
KVKatrien Vandendriessche
Katrien Vandendriessche
KDKarlien Degezelle
Karlien Degezelle
KVKristof Van de Voorde
Kristof Van de Voorde
FBFrancis De Burghgraeve
Francis De Burghgraeve
FRFilip Rega
Filip Rega

28 December 2023 in BMJ Open
Verified
Journal Article
Open access
PDF file
JBJanne Brouckaert
Janne Brouckaert
GDGöran Dellgren
Göran Dellgren
AWAndreas Wallinder
Andreas Wallinder
FRFilip Rega
Filip Rega
Introduction Ischaemic cold static storage (ICSS) is the gold standard in donor heart preservation. This ischaemic time frame renders a time constraint and risk for primary graft dysfunction. Cold oxygenated heart perfusion, known as non-ischaemic heart preservation (NIHP), theoretically limits the ischaemic time, while holding on to the known advantage of hypothermia and cardioplegia, a low metabolic rate. Methods and analysis The NIHP 2019 study is an international, randomised, controlled, open, multicentre clinical trial in 15 heart transplantation centres in 8 European countries and includes 202 patients undergoing heart transplantation, allocated 1:1 to NIHP or ICSS. Enrolment is estimated to be 30 months after study initiation. The patients are followed for 12 months after transplantation. The primary objective is to evaluate the effect of NIHP on survival, allograft function and rejection episodes within the first 30 days after transplantation. The secondary objectives are to compare treatment groups with respect to survival, allograft function, cardiac biomarkers, rejection episodes, allograft vasculopathy, adverse events and adverse device effects within 12 months. Ethics and dissemination This protocol was approved by the Ethics Committee (EC) for Research UZ/KU Leuven, Belgium, the coordinating EC in Germany (Bei Der LMU München), the coordinating EC in the UK (West Midlands—South Birmingham Research), the EC of Hospital Puerta de Hierro, Madrid, Spain, the EC of Göteborg, Sweden, the coordinating EC in France, the EC of Padova, Italy and the EC of the University of Vienna, Austria. This study will be conducted in accordance with current local regulations and international applicable regulatory requirements according to the principles of the Declaration of Helsinki and ISO14155:2020. Main primary and secondary outcomes will be published on modified intention-to-treat population and per-protocol population. Trial registration number NCT03991923.

1 November 2024 in Annals of Cardiothoracic Surgery
Verified
Journal Article
Open access
PDF file
DRDirk Van Raemdonck
Dirk Van Raemdonck
JBJanne Brouckaert
Janne Brouckaert
JSJan Van Slambrouck
Jan Van Slambrouck
KVKatrien Vandendriessche
Katrien Vandendriessche
LCLaurens J Ceulemans
Laurens J Ceulemans
FRFilip Rega
Filip Rega
The thoracic surgeon perspective—lung transplantation in controlled donation after circulatory determination of death: any conflict with the heart?

16 August 2022 in Clinical Transplantation
Verified
Journal Article
Closed access
CVChristophe Vandenbriele
Christophe Vandenbriele
JBJanne Brouckaert
Janne Brouckaert
GHGrégory Hans
Grégory Hans
VTVincent Tchana-Sato
Vincent Tchana-Sato
KVKatrien Vandendriessche
Katrien Vandendriessche
FRFilip Rega
Filip Rega

7 October 2025 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Open access
NCNicholas J.S. Chilvers
Nicholas J.S. Chilvers
KVKatrien Vandendriessche
Katrien Vandendriessche
NMNiels Moeslund
Niels Moeslund
MBMarius Berman
Marius Berman
JBJanne Brouckaert
Janne Brouckaert
LKLouise Kenny
Louise Kenny
The number of children referred for advanced heart failure management is increasing and with it the demand for heart transplant. However, transplantation rates have declined and waiting list mortality is up to 25%. While donation after circulatory death (DCD) heart recovery has increased adult transplant activity significantly, barriers have prevented the same in pediatrics. In the UK and Belgium, we have adopted hypothermic oxygenated perfusion (HOPE) to address this inequity. Preclinical: A porcine DCD-HOPE model was developed to simulate neonatal and infant heart recovery, preservation, and transplantation, including functional assessment. Hearts were recovered from 6 pediatric donors (3 DCD and 3 donation after brainstem death), aged 16 months-13 years), preserved with HOPE and transplanted. For small donors, this required a pediatric research cannula and surgical techniques, such as arch augmentation. In the preclinical model, porcine infant hearts could be successfully recovered, perfused, and transplanted with good cardiac output postbypass. In the clinical series, hearts from donors as small as 9 kg were successfully recovered, perfused, and transplanted. For the DCD cohort, median functional warm ischemic time was 19 minutes and there was no severe primary graft dysfunction. Survival at follow-up (median 287.5 days) was 100% and echocardiograms showed normal systolic function. There is great need to facilitate DCD heart recovery for infants and neonates. We have reported our outcomes from the world's first and smallest pediatric DCD-HOPE heart transplants and demonstrated that HOPE provides the long-awaited solution for pediatric DCD donation down to even neonatal donors. We call upon clinicians and policymakers to support DCD-HOPE to provide equity for child donors and recipients.